Table 3.

Prevalence of aspirin use for secondary CVD prevention by select demographic characteristics, 2012–2015.

			Prevalence trend, 2012–2015
	Prevalencea	95% CI	Average annual rate of change, %	pb
All adults 40 +	8.0%	7.9–8.1	− 3.6%	0.015
Age group
40–49	1.9%	1.7–2.1	− 12.0%	0.032
50–64	6.8%	6.5–7.1	− 6.5%	0.009
≥ 65	16.9%	16.4–17.5	− 3.3%	0.081
Sex
Male	10.3%	10.1–10.5	− 2.0%	0.312
Female	6.1%	5.9–6.2	− 5.8%	0.006
Race
Non-Hispanic white	8.2%	8.1–8.3	− 2.5%	0.152
Non-Hispanic black	8.8%	8.5–9.1	− 3.4%	0.360
Hispanic	6.4%	6.2–6.7	− 5.4%	0.199
Other	6.3%	5.9–6.7	− 12.6%	0.060
Geographic region
Northeast	7.1%	6.8–7.3	− 3.2%	0.369
Midwest	9.2%	8.9–9.4	3.3%	0.287
South	8.8%	8.6–9.1	− 7.3%	0.001
West	6.2%	6.0–6.3	− 5.8%	0.083
Household income
$0–$34,999	10.9%	10.7–11.1	− 4.3%	0.034
$35,000–$74,999	8.1%	7.8–8.3	− 0.3%	0.921
$75,000–$99,999	6.2%	5.8–6.5	2.8%	0.581
$100,000 and over	5.8%	5.6–6.1	− 0.7%	0.874
Health insurance
Not covered	5.0%	4.4–5.6	− 17.2%	0.006
Covered	8.1%	8.0–8.2	− 4.1%	0.006
BMI
Underweight	7.8%	6.8–8.8	− 4.3%	0.680
Normal	6.0%	5.9–6.2	− 6.1%	0.025
Overweight	8.1%	7.9–8.3	− 5.4%	0.014
Obese	9.6%	9.4–9.8	− 0.7%	0.767
Education
< High school	9.9%	9.4–10.4	− 0.6%	0.901
High school	9.2%	9.0–9.4	− 2.8%	0.172
≥ College	7.0%	6.9–7.2	− 4.0%	0.043

^aAge-adjusted to the 2000 standard US population.

^bp-Values are for trend significance via Wald F test, adjusted for age.